EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Dendritic cells pulsed with multifunctional Wilms’ tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer

Shigeo Koido iD, Junichi Taguchi, Masamori Shimabuku, Shin Kan, Tuuse Bito, Takeyuki Misawa, Zensho Ito, Kan Uchiyama, Masayuki Saruta, Shintaro Tsukinaga, Machi Suka, Hiroyuki Yanagisawa und 4 weitere

Journal for ImmunoTherapy of Cancer · 2024-10 · 12 (10) · e009765

DOI: 10.1136/jitc-2024-009765 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 08.10.2024. Verfasst von Shigeo Koido und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Japan shigeo_koido@jike…. Hauptthemen laut MEDLINE: WT1 Proteins, Pancreatic Neoplasms, Dendritic Cells, Tumor Microenvironment. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Education, Cultures.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to develop a chemoimmunotherapy regimen consisting of a novel Wilms’ tumor 1 (WT1) peptide-pulsed dendritic cell (WT1-DC) vaccine and multiagent chemotherapy and to investigate the safety, clinical outcomes, and WT1-specific immune responses of patients with unresectable advanced pancreatic ductal adenocarcinoma (UR-PDAC) who received this treatment.

Methods

Patients with UR-PDAC with stage III disease (locally advanced (LA-PDAC; n=6)), stage IV disease (metastatic (M-PDAC; n=3)), or recurrent disease after surgery (n=1) were enrolled in this phase I study. The patients received one cycle of nab-paclitaxel plus gemcitabine alone followed by 15 doses of the WT1-DC vaccine independent of chemotherapy. The novel WT1 peptide cocktail was composed of a multifunctional helper peptide specific for major histocompatibility complex class II, human leukocyte antigen (HLA)-A*02:01, or HLA-A*02:06 and a killer peptide specific for HLA-A*24:02.

Results

The chemoimmunotherapy regimen was well tolerated. In the nine patients for whom a prognostic analysis was feasible, the clinical outcomes of long-term WT1 peptide-specific delayed-type hypersensitivity (WT1-DTH)-positive patients (n=4) were significantly superior to those of short-term WT1-DTH-positive patients (n=5). During chemoimmunotherapy, eight patients were deemed eligible for conversion surgery and underwent R0 resection (four patients with LA-PDAC, one patient with M-PDAC, and one recurrence) or R1 resection (one patient with M-PDAC), and one patient with LA-PDAC was determined to be unresectable. Long-term WT1-DTH positivity was observed in three of the four patients with R0-resected LA-PDAC. These three patients exhibited notable infiltration of T cells and programmed cell death protein-1+ cells within the pancreatic tumor microenvironment (TME). All patients with long-term WT1-DTH positivity were alive for at least 4.5 years after starting therapy. In patients with long-term WT1-DTH positivity, the percentage of WT1-specific circulating CD4+ or CD8+ T cells that produced IFN-γ or TNF-α was significantly greater than that in patients with short-term WT1-DTH positivity after two vaccinations. Moreover, after 12 vaccinations, the percentages of both circulating regulatory T cells and myeloid-derived suppressor cells were significantly lower in patients with long-term WT1-DTH-positive PDAC than in short-term WT1-DTH-positive patients.

Conclusions

Potent activation of WT1-specific immune responses through a combination chemoimmunotherapy regimen including the WT1-DC vaccine in patients with UR-PDAC may modulate the TME and enable conversion surgery, resulting in clinical benefits (Online supplemental file 1). Trial registration number jRCTc030190195.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WT1 ProteinsPancreatic NeoplasmsDendritic CellsTumor MicroenvironmentCancer VaccinesHumansMaleFemaleMiddle AgedAgedAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidinePaclitaxelGemcitabineCarcinoma, Pancreatic DuctalAlbuminsImmunotherapyAdult

Stichwörter der Autor:innen

DendriticImmunotherapyTumor infiltrating lymphocyte - TILTumor microenvironment - TMEVaccine

Substanzen

WT1 ProteinsCancer VaccinesWT1 protein, humanDeoxycytidinePaclitaxelGemcitabine130-nm albumin-bound paclitaxelAlbumins

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Japan shigeo_koido@jikei.ac.jp.
  • Tokyo Midtown Clinic, Minato-ku, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Japan.
  • Department of Surgery, The Jikei University Kashiwa Hospital, Kashiwa, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, Japan.
  • Department of Endoscopy, The Jikei University Kashiwa Hospital, Kashiwa, Japan.

ORCID-Profile: Shigeo Koido

Förderung

  • Ministry of Education, Cultures

Zitieren

APA

Koido, S., Taguchi, J., Shimabuku, M., Kan, S., Bito, T., Misawa, T., Ito, Z., Uchiyama, K., Saruta, M., Tsukinaga, S., Suka, M., Yanagisawa, H., Sato, N., Ohkusa, T., Shimodaira, S., & Sugiyama, H. (2024). Dendritic cells pulsed with multifunctional Wilms’ tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer. Journal for ImmunoTherapy of Cancer, 12(10), e009765. https://doi.org/10.1136/jitc-2024-009765

Vancouver

Koido S, Taguchi J, Shimabuku M, Kan S, Bito T, Misawa T, et al. Dendritic cells pulsed with multifunctional Wilms’ tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer. Journal for ImmunoTherapy of Cancer. 2024;12(10):e009765. doi:10.1136/jitc-2024-009765

BibTeX
@article{Koido2024,
  author = {Koido, Shigeo and Taguchi, Junichi and Shimabuku, Masamori and Kan, Shin and Bito, Tuuse and Misawa, Takeyuki and Ito, Zensho and Uchiyama, Kan and Saruta, Masayuki and Tsukinaga, Shintaro and Suka, Machi and Yanagisawa, Hiroyuki and Sato, Nobuhiro and Ohkusa, Toshifumi and Shimodaira, Shigetaka and Sugiyama, Haruo},
  title = {Dendritic cells pulsed with multifunctional Wilms’ tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {10},
  pages = {e009765},
  doi = {10.1136/jitc-2024-009765}
}
Kostenlos starten →